NCT06698861 - A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

February 6, 2025

Study Completion Date

February 6, 2025

Conditions

PK in Healthy Volunteers

Interventions

DRUG

PEG-MetHuG-CSF

Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2

DRUG

Neulasta (Amgen)

Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.

Trial Locations (1)

Mackay Memorial Hospital, Taipei, Taiwan, Taipei